Previous 10 | Next 10 |
Evofem's Phexxi Contraceptive Gel to be Offered by Female Telehealth Leader Favor (Formerly The Pill Club) PR Newswire -- Phexxi is the first and only hormone-free contraceptive in the Favor product portfolio -- SAN DIEGO , Jan. 12, 2023 /PRNewswire/ -- E...
Costco Adds Phexxi® to Member Prescription Program PR Newswire SAN DIEGO , Jan. 10, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced that Phexxi ® (lactic acid, citric acid, potassium bitartrate) has been added to the ...
Multiple New Insurance Wins Expand and Improve Access to Phexxi® for Millions of Women PR Newswire -- Medicaid improves Phexxi coverage for more than 3.7 million lives across 11 states -- -- Largest commercial insurer in Michigan and a marquis university plan ...
OTC Markets Group Grants Evofem Additional Time to File Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2022 PR Newswire SAN DIEGO , Dec. 29, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced that it has been grant...
Evofem Biosciences ( OTCQB:EVFM ) said a phase 3 trial of EVO100 (vaginal gel Phexxi) to prevent chlamydia and gonorrhea infection in women did not achieve its goals and that the company will not invest further in the development of STI clinical program due to financia...
Evofem Reports Top-Line Results from Phase 3 EVOGUARD Clinical Trial Evaluating EVO100 for Prevention of Chlamydia and Gonorrhea Infection in Women PR Newswire SAN DIEGO , Oct. 11, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) announced toda...
Evofem Biosciences Announces Approval of Phexxi in Nigeria PR Newswire -- First Regulatory Approval Outside the U.S. -- SAN DIEGO , Oct. 6, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM) today announced that its hormone-free cont...
Evofem Biosciences Announces Uplisting to OTCQB PR Newswire SAN DIEGO , Oct. 3, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM) announced today that the trading of its common shares has been upgraded to the OTCQB Venture Market from the ...
Evofem Announces Issuance of U.S. Patent Covering Phexxi® Composition of Matter PR Newswire -- Issuance of U.S. Patent No. 11,439,610 Further Strengthens Evofem's Intellectual Patent Portfolio -- -- Newly Issued Patent Expected to Provide Protectio...
Inventor of the Year Awarded to Developer of Phexxi® PR Newswire -- Dr. Donald Waller Honored by University of Illinois Chicago -- SAN DIEGO , Sept. 19, 2022 /PRNewswire/ -- Evofem Biosciences (OTCPK: EVFM) is plea...
News, Short Squeeze, Breakout and More Instantly...
Evofem Biosciences Inc. Company Name:
EVFM Stock Symbol:
NASDAQ Market:
Evofem Biosciences Inc. Website:
Aditxt (NASDAQ: ADTX) , a company dedicated to discovering, developing and deploying promising health innovations, along with its wholly owned subsidiary Adifem Inc., and Evofem Biosciences Inc. (OTCQB: EVFM) have amended and restated their previously announced merger agreement. Accor...
Evofem Acquires SOLOSEC, an FDA-Approved Single-Dose Treatment for Bacterial Vaginosis and Trichomoniasis Aditxt, Inc. (“Aditxt”) (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, announces this past Friday, July 12...
2024-06-27 10:57:17 ET This company is striving to change the narratives around women's healthcare and offering solutions that reinforce and improve them. And shares are responding positively to a recent partnership announcement. Women's health innovator %EvofemBiosciences Inc. (OTC...